Advent Pharmaceuticals has developed a novel inhaler which can compete with proprietary products, to provide a lower priced alternative for governments, insurers and patients.

Funding from Commercialisation Australia will help take Advent’s novel inhaler ‘g60’ through late stage development and regulatory milestones to commercialisation.